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Introduction
Men who have sex with men (MSM) remain dispropor-
tionately infected with HIV. MSM accounted for 53% of
the 56,300 new HIV infections in the US in 2006, despite
representing only 4% of the national male population
[1, 2]. This high HIV disease burden coincides with high
prevalence of non-injection substance use and alcohol
consumption among US MSM. A national MSM sample
found a 42% previous year prevalence for any non-injec-
tion substance use [3]. The recently released United States
National HIV/AIDS strategy highlights the need to address
substance use among MSM as a critical component of
reducing HIV incidence in the United States [4]. To
advance this goal, it is imperative to: (1) redress the
knowledge gaps on patterns of non-injection substance use
among substance using MSM (SUMSM); (2) improve upon
existing interventions; (3) develop effective, scalable
interventions for the spectrum of users; and (4) determine
how to best identify and address the structural and cultural
factors that may contribute to non-injection substance use
in the MSM population.
Non-injection substance use may increase susceptibility
to HIV infection in multiple ways [5, 6]. Many epidemi-
ological studies document the association between these
substances and sexual risk behaviors [7–24]. These sexual
risks are paralleled by high rates of incident and prevalent
HIV cases and sexually transmitted infections among
SUMSM. Most notably, methamphetamine, cocaine, pop-
pers, and alcohol use have each been associated with an
increased risk for HIV and other STD infections [9, 12, 24–
30]. The contribution of polysubstance use may also be
considerable [9, 28, 31].
Patterns of Substance Use among MSM
Drug use among MSM is not an all or nothing phenome-
non. There needs to be more emphasis on addressing the
speciﬁc patterns of non-injection substance use among
SUMSM, and what implications these patterns have for
intervention approaches. Most SUMSM are not drug-
dependent, but rather use episodically (i.e., using sub-
stances less than weekly). National HIV Behavioral Sur-
veillance (NHBS) data show that 69–86% of SUMSM
report less than weekly substance use [32–35]. Episodic
binge drinking is also common among high-risk MSM [36,
37]. Importantly, episodic patterns are associated with
high-risk sexual behaviors, suggesting that while perhaps
less concerning from a drug-dependence perspective, they
may nonetheless contribute substantially to HIV transmis-
sion rates among SUMSM [24, 38].
Polysubstance use patterns (i.e., taking more than one
substance concurrently, or periodically over a period of
time) are often the norm among SUMSM. For example,
exclusive of alcohol use, 93% of non-injection metham-
phetamine using MSM in the San Francisco NHBS sample
reported polysubstance use during the prior 12 months
before interview; similarly, 94% of cocaine and 90% of
poppers users reported using other substances [39]. In a
sample of HIV-positive methamphetamine using MSM,
95% of respondents were polysubstance users [40]. Similar
ﬁndings were reported among samples of MSM club drug
users and African American MSM [41–43]. Among various
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of three or more substances [44–48].
We need to better understand how to address the wide
spectrum of non-injection substance use patterns among
MSM. At one extreme are the substance-dependent MSM
for whom risk behavior and substance use morbidity may
be especially high. Yet, there is also the larger population
of MSM whose substance use is infrequent, but for whom it
is associated with harmful use and HIV risk. It is unclear
where on the substance use spectrum interventions should
be invested to have the maximum effectiveness. There is
also little understanding as to why, with overall substance
use being so prevalent among MSM, only a small pro-
portion develops dependence. Similarly, there is a paucity
of understanding as to why some MSM do not use sub-
stances, and what factors confer protective effects or rel-
ative resiliency with regard to substance use [49]. Finally,
how substance use patterns vary across the life trajectories
of MSM and how those variations coincide with major life
milestones (e.g., sexual debut, coming out, dating, aging,
etc.), remains largely unexplored.
Current Interventions
Interventions in Drug Treatment Settings
SUMSM intervention trials have largely mirrored tradi-
tional addiction research, with a focus on treating those
with drug dependence in substance use treatment settings.
Most interventions emphasize cognitive or psychosocial
approaches to reduce non-injection substance use and
related risks [5, 50, 51]. Some trials focusing on treatment-
seeking, methamphetamine-dependent MSM have been
associated with reduced substance use and sexual risk
behavior [52]. There is limited evidence that behavioral
interventions with gay-speciﬁc components have a greater
effect on reducing methamphetamine use, lending support
for developing more culturally tailored interventions [5].
The support for contingency management’s acceptability
and efﬁcacy is mixed [52, 53]. While intensive behavioral
interventions appear in some cases to reduce cocaine use
and sexual risk among general populations, there is little
evidence of what may work best among MSM [50, 51, 54,
55]. Similarly, for alcohol, the most commonly used sub-
stance among MSM, there is a marked paucity of behav-
ioral trials speciﬁc to the population [56, 57].
Interventions Outside of Drug Treatment Settings
Most SUMSM do not access drug treatment, reinforcing
the need to develop interventions outside of treatment
settings that may reduce HIV risk behavior [58–60].
Project MIX, one of the largest randomized controlled
trials speciﬁc to SUMSM to date, tested a group inter-
vention outside of treatment centers. The study focused on
reducing sexual risk behavior, taking a risk-reduction
approach rather than an abstinence-based approach. Project
MIX enrolled a diverse cohort of SUMSM, including
polysubstance users and SUMSM of color. Compared to an
attention control arm, the intervention was not more efﬁ-
cacious in reducing sexual risk behaviors or substance use;
substantial reductions occurred in both arms [61]. Another
recent trial evaluating motivational interviewing among
MSM club drug users found signiﬁcant reductions in self-
reported club drug use in the intervention arm compared
with the control arm but only among the subset of non-
severely dependent participants. Moreover, the study found
no signiﬁcant differences in sexual risk reduction [62].
While these trials showed it is possible to enroll and retain
SUMSM in interventions outside of drug treatment set-
tings, and that participation is associated with reduced risk,
it remains to be determined which interventions are
efﬁcacious.
Pharmacologic Interventions for Dependent SUMSM
Given their cost, potential side effects, and the potential
monitoring required, it is likely that pharmaceutical treat-
ments would be targeted to dependent SUMSM, for whom
even intensive behavioral interventions may be insufﬁcient
to address the underlying chemical and psychological
changes that occur as a result of drug dependency. Like any
biomedical intervention, medications should not be viewed
as stand-alone interventions. Pharmacotherapies may have
the most potential to complement existing behavioral
strategies [55, 63]. A recent NIDA-funded study conducted
by our group determined that it was feasible to enroll and
retain methamphetamine-dependent, actively-using MSM
in a pharmacologic trial with a behavioral platform of risk-
reduction counseling [64]. Unfortunately, effective phar-
macotherapies for most non-injection substances, including
cocaine and methamphetamine, remain elusive [5, 55, 65,
66]. While a variety of medications have shown efﬁcacy in
reducing alcohol use, we are unaware of published studies
demonstrating their acceptability among MSM, or their
efﬁcacy in reducing alcohol-related sexual risk behavior.
Because of the high prevalence of polysubstance use
among SUMSM, medications that can help reduce depen-
dence on various classes of drugs may be optimal. One
promising option is naltrexone, an FDA approved medi-
cation to treat alcohol dependence that in one study
reduced amphetamine relapse [67]. Given the potential
barriers to medication adherence among non-injection
substance users, interventions with adherence support
and formulations that will minimize patient burden (e.g.,
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ing) could be explored [68, 69].
Future Research Directions for SUMSM Outside
of Drug Treatment Settings
The Centers for Disease Control and Prevention-funded
Project ECHO study is an ongoing behavioral intervention
trial for non-treatment seeking MSM who are episodic sub-
stance users (clinicaltrials.gov identiﬁer: NCT01279044)
[70]. The study will determine whether brief, personalized
cognitive risk-reduction counseling is effective in reducing
sexual risk behavior in the setting of substance use. This
study’sunderlyinghypothesisisthatabriefinterventionmay
be sufﬁcient to change risk among non-dependent, episodic
users whose lives may be less complicated by substance
abuse-related factors compared with drug-dependent MSM
[70].
Speciﬁc areas that may require increased attention
include settings and dimensions that facilitate non-injection
substance use among MSM, such as party events, sex
clubs, and websites that cultivate the ‘‘party and play’’ (i.e.,
sex with drugs) subculture. Potential interventions that may
warrant further investigation include: Ghaziani and Cook’s
5-by-5 circuit party matrix strategy of engaging critical
circuit party stakeholders and participants by using theo-
retically-based harm reduction messages; Internet-based
outreach strategies such as the ‘‘Cyber-Based Education
and Referral/Men for Men’’ (CyBER/M4 M); and behav-
ioral change theory-based risk reduction interventions
delivered via mobile text messages or smartphone appli-
cations to MSM [71–74]. Other programs for SUMSM,
such as support groups, economic incentive programs, and
mobile harm reduction services, could be implemented and
tested in community settings to engage hard to reach
populations [75–77]. The effectiveness of these interven-
tions in reducing HIV risk, substance use, and substance
use-related harms needs to be proven.
Addressing Other Health Needs of SUMSM
Routine testing for HIV and other sexually transmitted
infections should also be expanded among SUMSM. Given
the high rates of sexual risk associated with this population,
screening every 3–6 months is prudent. Other important
general healthcare approaches include outreach efforts to
expand HIV testing and treatment among SUMSM not
engaged in care, expanding beyond partner notiﬁcation to
encourage for routine testing for sex partners and social
network associates of SUMSM. As is the case with sub-
stance users in general, ongoing non-injection substance
use should not preclude consideration of antiretroviral
therapy (ART) for HIV-infected SUMSM. Aggressive
efforts should be made to effectively engage HIV-positive
SUMSM into care and provide support necessary for vol-
untary initiation of ART and attendant virologic suppres-
sion for their own individual health beneﬁt, as well as to
reduce forward transmission. The National Institute of
Health’s ‘‘Test and Treat’’ initiatives, including NIDA’s
support for ‘‘Seek, Test, Treat and Retain’’ research, may
be excellent opportunities to determine how to best get
SUMSM tested and into medical care [78, 79].
Additionally, SUMSM may have co-morbidities or life
experiences that additively exacerbate susceptibility to
HIV infection and may perpetuate substance use [49].
These may include mental illness, post-traumatic stress,
sexual trauma, domestic violence and other underlying
sociocultural factors [5, 49, 59, 80, 81]. How to best
intervene on these multiple, intertwined and highly com-
plex factors that converge to create ‘‘syndemics’’ among
MSM remains an area of active research [80, 82].
Structural Factors
The structural factors that may contribute to substance use
among MSM remain largely unexplored and under-
researched. This is concerning because addressing these
factors to improve MSM health overall may have a larger
population-level impact than individual interventions [83].
Certainly, legalizing syringe exchange and making clean
supplies available to injectors can be expected to beneﬁt
the SUMSM who inject [84]. However, it is unclear what
other policies, laws, or social forces contribute to the high
prevalence of non-injection substance use and related
harms, including sexual risk, among MSM. Substance use
is a largely criminalized and stigmatized practice. Evidence
shows limited success from prohibitive approaches to drug
control. For example, precursor regulation for metham-
phetamine production had mixed and mostly short-term
effects on the supply and purity of the drug [5, 85].
Decriminalization may reduce substance use-related harms
[86–88]. ‘‘Wars on drugs’’ are expensive, have little or no
apparent effect, and in some cases have led to catastrophic
casualties and egregious human rights violations [5, 86,
89]. In recognition of these failures, The Vienna Declara-
tion, released at the XVIII International AIDS Conference,
calls for reorienting drug policies toward those that are
evidence-based [86].
Conclusion
SUMSM are at high risk for HIV infection, yet there are
critical gaps in knowledge regarding the contribution of
non-injection substance use to the HIV epidemic among
US MSM. The ﬁeld will beneﬁt from additional insights on
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predictors of different drug use trajectories. Substance
treatment and HIV prevention services should be employed
to address the needs of SUMSM. Efforts to develop evi-
dence-based interventions need to be accelerated. Empha-
sis should be placed on ﬁnding sustainable, effective
strategies that deal with non-injection substance use and
risk for HIV infection. While we have focused on US
MSM, emerging evidence indicates that non-injection
substance use is also driving the MSM HIV epidemic in
other regions; yet, the majority of intervention trials have
been conducted within the US and other Western countries
[5, 90–94]. Ultimately, researchers should strive to develop
efﬁcacious intervention strategies that are scalable, cost-
effective and sustainable for the diversity of SUMSM.
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